Scholarlink

Propose <p>This study aimed to evaluate the efficacy and safety of neoadjuvant treatment of darolutamide, a next-generation androgen receptor inhibitor, plus androgen deprivation therapy (ADT) for patients with locally advanced prostate cancer (LAPC).</p> Methods <p>This single-arm, multicenter, open-label phase II trial (ClinicalTrials.gov: NCT05249712, 2022-01-01), recruited 30 localized high-risk/very high-risk prostate cancer (HRPCa/VHRPCa) patients from three centers in China between 2021 and 2023. Following six months of neoadjuvant therapy combining darolutamide with ADT, the patients underwent radical prostatectomy (RP). The primary endpoint is pathologic complete response (pCR) or minimal residual disease (MRD). The secondary endpoints are progression-free survival (PFS), positive surgical margin rate and safety. Exploratory endpoint was the relationship between postoperative ctDNA and primary outcome.</p> Results <p>The pCR or MRD rate was 40%(<i>n</i> = 12). Only four patients (13.3%) had positive surgical margins. The 12 months PFS was 90.0% (95% CI, 74.4–96.5%). The detection of circulating tumor DNA (ctDNA) accurately predicts the disease progression. No grade 3 or 4 adverse events were observed. The most frequent adverse events included hot flashes and elevated alanine aminotransferase or aspartate transaminase levels, which were observed in three patients (10%).</p> Conclusion <p>Neoadjuvant therapy with darolutamide plus ADT for six months followed by RP is effective and safe for HRPCa and LAPC. The detection of ctDNA can predict disease progression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial

  • 期刊论文

  • 发表日期：

    2025年1月3日

查看全文
  • Xuyu Zhang,
  • Feng Zhou,
  • Tong Lu,
  • Shun Zhang,
  • Xuedong Wei,
  • Xuefeng Qiu,
  • Linfeng Xu,
  • Hongqian Guo,
  • Junlong Zhuang

摘要

Propose

This study aimed to evaluate the efficacy and safety of neoadjuvant treatment of darolutamide, a next-generation androgen receptor inhibitor, plus androgen deprivation therapy (ADT) for patients with locally advanced prostate cancer (LAPC).

Methods

This single-arm, multicenter, open-label phase II trial (ClinicalTrials.gov: NCT05249712, 2022-01-01), recruited 30 localized high-risk/very high-risk prostate cancer (HRPCa/VHRPCa) patients from three centers in China between 2021 and 2023. Following six months of neoadjuvant therapy combining darolutamide with ADT, the patients underwent radical prostatectomy (RP). The primary endpoint is pathologic complete response (pCR) or minimal residual disease (MRD). The secondary endpoints are progression-free survival (PFS), positive surgical margin rate and safety. Exploratory endpoint was the relationship between postoperative ctDNA and primary outcome.

Results

The pCR or MRD rate was 40%(n = 12). Only four patients (13.3%) had positive surgical margins. The 12 months PFS was 90.0% (95% CI, 74.4–96.5%). The detection of circulating tumor DNA (ctDNA) accurately predicts the disease progression. No grade 3 or 4 adverse events were observed. The most frequent adverse events included hot flashes and elevated alanine aminotransferase or aspartate transaminase levels, which were observed in three patients (10%).

Conclusion

Neoadjuvant therapy with darolutamide plus ADT for six months followed by RP is effective and safe for HRPCa and LAPC. The detection of ctDNA can predict disease progression.